These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27995438)

  • 1. Urate as a Marker of Risk and Progression of Neurodegenerative Disease.
    Paganoni S; Schwarzschild MA
    Neurotherapeutics; 2017 Jan; 14(1):148-153. PubMed ID: 27995438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
    Cipriani S; Chen X; Schwarzschild MA
    Biomark Med; 2010 Oct; 4(5):701-12. PubMed ID: 20945982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.
    Basile MS; Bramanti P; Mazzon E
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urate in Parkinson's disease: more than a biomarker?
    Chen X; Wu G; Schwarzschild MA
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):367-75. PubMed ID: 22580741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting urate to reduce oxidative stress in Parkinson disease.
    Crotty GF; Ascherio A; Schwarzschild MA
    Exp Neurol; 2017 Dec; 298(Pt B):210-224. PubMed ID: 28622913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.
    Zhang C; Yang Y; Liang W; Wang T; Wang S; Wang X; Wang Y; Jiang H; Feng H
    Brain Res Bull; 2019 Mar; 146():287-301. PubMed ID: 30690059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
    ; Schwarzschild MA; Ascherio A; Beal MF; Cudkowicz ME; Curhan GC; Hare JM; Hooper DC; Kieburtz KD; Macklin EA; Oakes D; Rudolph A; Shoulson I; Tennis MK; Espay AJ; Gartner M; Hung A; Bwala G; Lenehan R; Encarnacion E; Ainslie M; Castillo R; Togasaki D; Barles G; Friedman JH; Niles L; Carter JH; Murray M; Goetz CG; Jaglin J; Ahmed A; Russell DS; Cotto C; Goudreau JL; Russell D; Parashos SA; Ede P; Saint-Hilaire MH; Thomas CA; James R; Stacy MA; Johnson J; Gauger L; Antonelle de Marcaida J; Thurlow S; Isaacson SH; Carvajal L; Rao J; Cook M; Hope-Porche C; McClurg L; Grasso DL; Logan R; Orme C; Ross T; Brocht AF; Constantinescu R; Sharma S; Venuto C; Weber J; Eaton K
    JAMA Neurol; 2014 Feb; 71(2):141-50. PubMed ID: 24366103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urate as a marker of development and progression in Parkinson's disease.
    Constantinescu R; Zetterberg H
    Drugs Today (Barc); 2011 May; 47(5):369-80. PubMed ID: 22013567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.
    Schwarzschild MA; Macklin EA; Bakshi R; Battacharyya S; Logan R; Espay AJ; Hung AY; Bwala G; Goetz CG; Russell DS; Goudreau JL; Parashos SA; Saint-Hilaire MH; Rudolph A; Hare JM; Curhan GC; Ascherio A;
    Neurology; 2019 Oct; 93(14):e1328-e1338. PubMed ID: 31484712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    ; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
    JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urate as a predictor of the rate of clinical decline in Parkinson disease.
    Ascherio A; LeWitt PA; Xu K; Eberly S; Watts A; Matson WR; Marras C; Kieburtz K; Rudolph A; Bogdanov MB; Schwid SR; Tennis M; Tanner CM; Beal MF; Lang AE; Oakes D; Fahn S; Shoulson I; Schwarzschild MA;
    Arch Neurol; 2009 Dec; 66(12):1460-8. PubMed ID: 19822770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide variant by serum urate interaction in Parkinson's disease.
    Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
    Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for Managing Neurodegenerative Diseases.
    Cheslow L; Snook AE; Waldman SA
    Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.
    Chen X; Umeh CC; Tainsh RE; Feng DD; Maguire M; Zuo F; Rahimian M; Logan R; Wang X; Ascherio A; Macklin EA; Buys ES; Schwarzschild MA;
    EBioMedicine; 2018 Nov; 37():259-268. PubMed ID: 30415890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
    Schwarzschild MA; Schwid SR; Marek K; Watts A; Lang AE; Oakes D; Shoulson I; Ascherio A; ; Hyson C; Gorbold E; Rudolph A; Kieburtz K; Fahn S; Gauger L; Goetz C; Seibyl J; Forrest M; Ondrasik J
    Arch Neurol; 2008 Jun; 65(6):716-23. PubMed ID: 18413464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
    Bhattacharyya S; Bakshi R; Logan R; Ascherio A; Macklin EA; Schwarzschild MA
    Mov Disord; 2016 Mar; 31(3):417-21. PubMed ID: 26805433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.
    Pathak N; Vimal SK; Tandon I; Agrawal L; Hongyi C; Bhattacharyya S
    Metab Brain Dis; 2022 Jan; 37(1):67-104. PubMed ID: 34719771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release.
    Bakshi R; Zhang H; Logan R; Joshi I; Xu Y; Chen X; Schwarzschild MA
    Neurobiol Dis; 2015 Oct; 82():574-579. PubMed ID: 26341543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbiased metabolome screen links serum urate to risk of Alzheimer's disease.
    Şanlı BA; Whittaker KJ; Motsi GK; Shen E; Julian TH; Cooper-Knock J
    Neurobiol Aging; 2022 Dec; 120():167-176. PubMed ID: 36206691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
    Iwaki H; Ando R; Miyaue N; Tada S; Tsujii T; Yabe H; Nishikawa N; Nagai M; Nomoto M
    J Neurol Sci; 2017 Dec; 383():75-78. PubMed ID: 29246629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.